Overview

• Among 832 metastatic patients, high Decipher scores were linked to a 36% lower risk of death with docetaxel, while low scores showed an estimated benefit of under 4%.
• The molecular analysis drew on 1,523 STAMPEDE phase III participants starting androgen-deprivation therapy, with a median follow-up of 14 years.
• A transcriptomic signature of PTEN inactivity predicted poorer outcomes on hormone therapy and greater relative benefit from chemotherapy.
• The Decipher Prostate assay is already used in the United States for localized disease and now has trial-linked evidence supporting use in metastatic treatment selection.
• Researchers say the approach can help target chemotherapy to those most likely to benefit and spare others unnecessary toxicity, with the work enabled by a UCL–Veracyte collaboration and charity funding.